Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


SepMate™-50: For Hassle-Free PBMC Isolation in Just 15 Minutes

Product Image
Product Description

SepMate™ -50 is a new tube that enables consistent and hassle-free PBMC isolations in just 15 minutes. The unique SepMate™ insert lets you quickly layer blood over the density gradient medium, and prevents the layers from mixing. After centrifugation with the brake on, PBMCs are simply poured into a fresh tube.

Advantages of SepMate™-50:

• EASY: Say goodbye to slow and laborious sample layering over the density gradient medium.
• FAST: Centrifuge for just 10 minutes with the brake on.
• CONSISTENT: Minimize variability between separations. 

SepMate™-50 can also be combined with RosetteSep™, the unique immunodensity-based cell isolation reagent, to isolate highly purified immune cells from whole blood in as little as 25 minutes.

To learn more, view the video protocol or request a free sample, visit the link below.

Product SepMate™-50: For Hassle-Free PBMC Isolation in Just 15 Minutes
Company StemCell Technologies
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

StemCell Technologies
40 Rues des Berges Miniparc Polytec Bâtiment Sirocco, 38000 Grenoble France

Tel: +33.(0)4.76.04.75.30
Fax: +33.(0).4.76.18.99.63
Email: Product.management@stemcell.com



Scientific News
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Iron Regulators Join War on Pathogens
Iron regulatory proteins (IRPs) play an important role in the body’s immune system.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!